Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company whose news flow centers on the development of its INTASYL® gene silencing technology and lead compound PH-762. Company announcements describe INTASYL as a gene silencing platform focused on immuno-oncology therapeutics, with PH-762 targeting the PD-1 gene implicated in various forms of skin cancer.
News about Phio frequently covers clinical trial milestones for PH-762. The company has reported completion of enrollment in its ongoing Phase 1b dose escalation trial (NCT 06014086), interim pathology results in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and safety reviews by its Safety Monitoring Committee. Updates have included detailed response rates, such as complete, near complete, and partial responses based on tumor clearance, as well as statements that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed in the cohorts reported.
Phio also issues regulatory and development updates, including acceptance by the U.S. Food and Drug Administration of its nonclinical protocol study design for a toxicology study required before a pivotal trial of PH-762. Additional news items describe agreements with a U.S. manufacturer for cGMP clinical supply of PH-762 and progress toward delivering commercially viable drug product.
Investors following PHIO news will also see financing and corporate announcements, such as warrant inducement transactions, cash runway commentary, and board-level changes, including the appointment of a Lead Independent Director. The company regularly participates in investor conferences and scientific meetings, where it presents INTASYL technology and PH-762 data, and has highlighted external recognition such as PH-762 being named “Immunomodulatory Solution of the Year” in the BioTech Breakthrough Awards.
This news page aggregates these clinical, regulatory, financing, and governance updates so readers can track how Phio’s INTASYL platform and PH-762 program are progressing over time.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising results from a recent in vivo study demonstrating the enhanced efficacy of its INTASYL pipeline products when combined. The data, presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer, shows that combining INTASYL compounds significantly improves tumor control compared to monotherapy. The compounds target PD-1, PD-L1, and TIGIT proteins linked to immune suppression in cancer. These findings suggest a potential breakthrough in the treatment of solid tumors, increasing the therapeutic options available for patients.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced three upcoming poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), occurring virtually from November 9-14, 2020. The poster presentations highlight INTASYL compounds, a proprietary self-delivering RNAi therapeutic platform. Notably, findings include a study on combination treatment using INTASYL targeting TIGIT and PD-1/PD-L1, revealing enhanced tumor control. The archived presentation will be accessible in the "Investors – Events and Presentations" section of the Company's website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that CEO Dr. Gerrit Dispersyn will present at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Dr. Dispersyn's presentation will take place on September 16 at 11:30 a.m. ET. Investors can access the live webcast here, with an archived version available on the Company's website afterward. Phio focuses on developing innovative immuno-oncology therapeutics using its proprietary self-delivering RNAi platform, INTASYL™.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its Q2 2020 financial results, highlighting significant advancements in its INTASYL™ RNAi therapeutic platform. Key developments include promising preclinical data from major conferences that demonstrate the safety and efficacy of INTASYL technology in targeting immune cells for cancer treatment. As of June 30, 2020, the company had $18.9 million in cash, up from $6.9 million at year-end 2019, aiding its operations for the next 12 months. The net loss was $1.7 million, a decrease compared to $2.0 million in Q2 2019.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced at the AACR 2020 Virtual Annual Meeting promising data from a study on PH-804, a TIGIT targeting INTASYL compound. The findings indicate significant tumor growth inhibition in a colorectal carcinoma model, showing PH-804's ability to silence TIGIT mRNA and enhance immune cell activation in the tumor microenvironment. This data supports the compound's potential as a viable alternative to anti-TIGIT antibodies.